筋消耗性疾患の世界市場：成長、将来展望、競合分析、2024～2032年

筋消耗性疾患は、筋肉量や筋力の著しい減少を特徴とする疾患で、近年、医学的な関心が高まっています。このような疾患には、加齢に伴うサルコペニアから筋ジストロフィーのような神経筋疾患まで、さまざまな疾患が含まれます。筋消耗性疾患の市場規模は、2024～2032年にかけてCAGR 15.5％で成長すると推定されます。

促進要因：高齢化人口の増加とそれに伴うサルコペニア

筋消耗性疾患市場の主な促進要因の1つは、世界の高齢化人口の急激な増加です。ベビーブーマー世代が高齢者層に入るにつれ、サルコペニア（加齢と密接に関連する筋力低下状態）の有病率が急増しています。国連の世界人口高齢化に関する報告書によると、60歳以上の高齢者の数は2050年までに倍増すると予想されています。この人口動態の変化により、サルコペニアの症例が増加しています。筋肉の衰えは、身体障害、転倒、骨折、総死亡のリスクを指数関数的に増大させるという事実も重なり、ヘルスケア産業はこの疾患との闘いに力を注いでいます。ホルモン補充療法から筋力トレーニングレジメンまで幅広い治療戦略が注目されており、この市場の可能性が拡大していることを示しています。

機会：神経筋疾患に対する遺伝子治療の進歩

遺伝子治療の領域は、特定の筋消耗性疾患、特に筋ジストロフィーのような遺伝性疾患の根本原因への対処において有望な成果を示しています。最近のケーススタディでは、遺伝子治療が特定の遺伝子の導入や修正に成功し、筋機能の改善や疾患の進行抑制につながった事例が紹介されています。例えば、『New England Journal of Medicine』誌に掲載された論文では、特定のタイプの筋ジストロフィーを持つ小児の運動機能の改善を示した遺伝子治療試験について詳述されています。遺伝子研究が進み、これらの疾患の原因となる変異が明らかになるにつれ、標的療法を開発する機会が拡大し、治療の展望が大きく変わる可能性があります。

抑制要因：高い治療費と限られたアクセス性

治療と管理の進歩は有望であるが、その代償は大きいです。最先端の治療、特に遺伝子治療には法外な費用がかかります。これらの治療の多くは保険適用外であり、患者に大きな経済的負担を強いています。さらに、主に低・中所得国では、専門的な治療センターが限られているため、治療へのアクセスが制限されています。Journal of Clinical Medicine誌に掲載された研究では、地域によって神経筋疾患治療の利用可能性に大きな格差があることが強調され、世界の普及を達成するための市場の課題が明らかにされました。

課題臨床像の多様性と診断の難しさ

筋消耗性疾患では、臨床症状のばらつきが大きく、早期診断が困難な場合が多いです。進行の管理にはタイムリーな介入が重要であることを考えると、この診断の遅れは患者の転帰を危うくする可能性があります。筋生検は、特定の筋消耗性疾患の診断におけるゴールドスタンダードの一つであるが、侵襲的であり、必ずしも決定的な結果が得られるとは限らないです。Muscle & Nerve誌に掲載された論文では、筋生検で非特異的な結果が得られ、さらなる診断処置が必要となった例を取り上げています。このようなばらつきは、診断にかかる時間を長引かせるだけでなく、これらの障害に伴う精神的・経済的苦痛を増幅させます。

タイプ別市場セグメンテーション

収益の面では、筋ジストロフィーが2023年の市場セグメントを牽引しました。これは、特に小児人口におけるその有病率と、理学療法、外科的介入、薬物療法を含むその管理に関連する高額な費用に起因しています。筋ジストロフィー、特にデュシェンヌ型筋ジストロフィー（DMD）に対する研究の焦点は、遺伝子治療やエクソンスキッピング薬のような治療の革新に道を開き、収益のエンベロープをさらに押し上げました。対照的に、筋萎縮症はALS、脊髄性筋萎縮症、神経損傷などの神経筋疾患や病態の結果として発症することが多く、年間平均成長率（CAGR）が最も高いです。認知度の向上、早期診断介入、脊髄性筋萎縮症（SMA）のような疾患に対する治療パイプラインの急増が、この成長軌道に寄与しており、2024～2032年まで継続すると予想されます。

エンドユーザー別市場セグメンテーション

2023年には、病院が筋消耗性疾患市場の主要な収益貢献者に浮上しました。この優位性は、診断、治療、手術、リハビリを含む包括的なケアを一つ屋根の下で提供することに起因しています。これらの疾患の管理には集学的アプローチが不可欠となり、病院の全人的ケアモデルが好まれるようになった。しかし、2024～2032年にかけては、リハビリセンターが最も高いCAGRを示すと予想されます。生活の質を向上させ、運動機能を維持し、病気の進行を遅らせることに重点が移ると、筋消耗性疾患管理におけるリハビリ療法の役割が最も重要になります。理学療法、作業療法、言語療法などを専門とするセンターは、ますます重要性を増しています。また、ニッチな治療分野に特化した専門クリニックや、在宅ケアのような他の分野も重要な役割を果たしており、患者は個別化された専門治療を求めたり、快適な自宅での治療を好んだりしています。

地域別市場セグメンテーション

高度なヘルスケアインフラ、調査イニシアティブ、患者の意識を有する北米が、2023年に最大の売上シェアを占めました。DMDやSMAのような疾患に対する薬剤のFDAによる承認と大手製薬企業の存在が、この地域の優位性を後押ししました。しかし、アジア太平洋地域は2024～2032年にかけて最も高いCAGRを示すと予測されています。医療費の増加、筋消耗性疾患に対する意識の高まり、診断インフラの改善といった要因が、この予測成長に寄与しています。さらに、急増する人口と未開拓市場の存在は、この地域の市場拡大に有利な機会をもたらしています。

競合動向

筋消耗性疾患市場は激しい競争を特徴としており、Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd.が2023年の主導権を握りました。これらの企業は主に、市場での地位を維持するために、合併、買収、調査提携、積極的な研究開発投資などの戦略に重点を置いています。例えば、RocheによるSpark Therapeuticsの買収は、特に筋消耗性疾患に関する遺伝子治療分野での足場を固めました。さらに、患者支援プログラムを重視することで、高額な費用がかかっても医薬品を入手しやすくすることが、注目すべき戦略となった。今後、2024～2032年にかけて、これらのプレーヤーは技術革新、共同研究、戦略的提携を継続し、市場を牽引していくと予想されます。

本レポートでお答えする主な質問

筋消耗性疾患市場の成長に影響を与えている主要なミクロおよびマクロ環境要因は何か？

現在および予測期間中の製品セグメントと地域に関する主な投資ポケットは？

2032年までの推定推計・市場予測

予測期間中にCAGRが最も速いセグメントは？

市場シェアの大きいセグメントとその理由は？

中低所得国は筋消耗性疾患市場に投資しているか？

筋消耗性疾患市場で最大の地域市場はどこか？

アジア太平洋、ラテンアメリカ、中東・アフリカなどの新興市場における市場動向と力学は？

筋消耗性疾患市場の成長を促進する主要動向は？

世界の筋消耗性疾患市場で存在感を高めるための主要な競合企業とその主要戦略とは？

目次

第1章 序文

• レポート内容
  • レポートの目的
  • 対象者
  • 主な提供
• 市場セグメンテーション
• 調査手法
  • フェーズⅠ - 二次調査
  • フェーズⅡ - 一次調査
  • フェーズⅢ - 有識者レビュー
  • 前提条件
  • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 筋消耗性疾患市場：競合分析

• 主要ベンダーの市場ポジショニング
• ベンダーが採用した戦略
• 主要な産業戦略
• ティア分析：2023年 vs 2032年

第4章 筋消耗性疾患市場：マクロ分析と市場力学

• イントロダクション
• 世界の筋消耗性疾患市場金額、2022～2032年
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因と抑制要因の影響分析
• シーソー分析
• ポーターのファイブフォースモデル
  • 供給企業の力
  • 買い手の購買力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • 技術情勢
  • 法的情勢
  • 社会情勢

第5章 筋消耗性疾患市場：タイプ別、2022～2032年

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • 筋ジストロフィー
  • 筋萎縮症

第6章 筋消耗性疾患市場：治療タイプ別、2022～2032年

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • 薬物療法
  • 理学療法
  • 栄養療法
  • 外科療法
  • 遺伝子治療
  • その他

第7章 筋消耗性疾患市場：エンドユーザー別、2022～2032年

• 市場概要
• 成長・収益分析：2023年 vs 2032年
• 市場セグメンテーション
  • 病院
  • リハビリセンター
  • 専門クリニック
  • その他

第8章 北米の筋消耗性疾患市場、2022～2032年

• 市場概要
• 筋消耗性疾患市場：タイプ別、2022～2032年
• 筋消耗性疾患市場：治療タイプ別、2022～2032年
• 筋消耗性疾患市場：エンドユーザー別、2022～2032年
• 筋消耗性疾患市場：地域別、2022～2032年
  • 北米
    • 米国
    • カナダ
    • その他の北米

第9章 英国・欧州連合の筋消耗性疾患市場、2022～2032年

• 市場概要
• 筋消耗性疾患市場：タイプ別、2022～2032年
• 筋消耗性疾患市場：治療タイプ別、2022～2032年
• 筋消耗性疾患市場：エンドユーザー別、2022～2032年
• 筋消耗性疾患市場：地域別、2022～2032年
  • 英国・欧州連合
    • 英国
    • ドイツ
    • スペイン
    • イタリア
    • フランス
    • その他の欧州

第10章 アジア太平洋の筋消耗性疾患市場、2022～2032年

• 市場概要
• 筋消耗性疾患市場：タイプ別、2022～2032年
• 筋消耗性疾患市場：治療タイプ別、2022～2032年
• 筋消耗性疾患市場：エンドユーザー別、2022～2032年
• 筋消耗性疾患市場：地域別、2022～2032年
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋

第11章 ラテンアメリカの筋消耗性疾患市場、2022～2032年

• 市場概要
• 筋消耗性疾患市場：タイプ別、2022～2032年
• 筋消耗性疾患市場：治療タイプ別、2022～2032年
• 筋消耗性疾患市場：エンドユーザー別、2022～2032年
• 筋消耗性疾患市場：地域別、2022～2032年
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他のラテンアメリカ

第12章 中東・アフリカの筋消耗性疾患市場、2022～2032年

• 市場概要
• 筋消耗性疾患市場：タイプ別、2022～2032年
• 筋消耗性疾患市場：治療タイプ別、2022～2032年
• 筋消耗性疾患市場：エンドユーザー別、2022～2032年
• 筋消耗性疾患市場：地域別、2022～2032年
  • 中東・アフリカ
    • GCC
    • アフリカ
    • その他の中東・アフリカ

第13章 企業プロファイル

• Biogen Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Ionis Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Nippon Shinyaku Co. Ltd.（NS Pharma Inc.）
• PTC Therapeutics Inc.
• Teva Pharmaceutical Industries Ltd.
• その他の主要企業

List of Tables

• TABLE 1 Global Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 2 Global Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 3 Global Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 4 Global Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 5 Global Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 6 Global Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 7 North America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 8 North America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 9 North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 10 North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 11 North America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 12 North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 13 U.S. Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 14 U.S. Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 15 U.S. Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 16 U.S. Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 17 U.S. Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 18 U.S. Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 19 Canada Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 20 Canada Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 21 Canada Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 22 Canada Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 23 Canada Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 24 Canada Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 25 Rest of North America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 26 Rest of North America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 27 Rest of North America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 28 Rest of North America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 29 Rest of North America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 30 Rest of North America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 31 UK and European Union Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 32 UK and European Union Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 33 UK and European Union Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 34 UK and European Union Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 35 UK and European Union Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 36 UK and European Union Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 37 UK Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 38 UK Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 39 UK Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 40 UK Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 41 UK Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 42 UK Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 43 Germany Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 44 Germany Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 45 Germany Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 46 Germany Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 47 Germany Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 48 Germany Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 49 Spain Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 50 Spain Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 51 Spain Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 52 Spain Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 53 Spain Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 54 Spain Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 55 Italy Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 56 Italy Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 57 Italy Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 58 Italy Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 59 Italy Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 60 Italy Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 61 France Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 62 France Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 63 France Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 64 France Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 65 France Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 66 France Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 67 Rest of Europe Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 68 Rest of Europe Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 69 Rest of Europe Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 70 Rest of Europe Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 71 Rest of Europe Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 72 Rest of Europe Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 73 Asia Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 74 Asia Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 75 Asia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 76 Asia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 77 Asia Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 78 Asia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 79 China Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 80 China Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 81 China Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 82 China Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 83 China Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 84 China Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 85 Japan Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 86 Japan Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 87 Japan Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 88 Japan Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 89 Japan Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 90 Japan Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 91 India Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 92 India Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 93 India Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 94 India Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 95 India Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 96 India Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 97 Australia Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 98 Australia Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 99 Australia Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 100 Australia Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 101 Australia Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 102 Australia Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 103 South Korea Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 104 South Korea Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 105 South Korea Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 106 South Korea Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 107 South Korea Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 108 South Korea Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 109 Latin America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 110 Latin America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 111 Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 112 Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 113 Latin America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 114 Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 115 Brazil Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 116 Brazil Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 117 Brazil Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 118 Brazil Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 119 Brazil Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 120 Brazil Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 121 Mexico Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 122 Mexico Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 123 Mexico Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 124 Mexico Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 125 Mexico Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 126 Mexico Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 127 Rest of Latin America Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 128 Rest of Latin America Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 129 Rest of Latin America Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 130 Rest of Latin America Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 131 Rest of Latin America Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 132 Rest of Latin America Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 133 Middle East and Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 134 Middle East and Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 135 Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 136 Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 137 Middle East and Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 138 Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 139 GCC Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 140 GCC Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 141 GCC Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 142 GCC Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 143 GCC Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 144 GCC Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 145 Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 146 Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 147 Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 148 Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 149 Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 150 Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

• TABLE 151 Rest of Middle East and Africa Muscle Wasting Disorders Market By Type, 2022-2032, USD (Million)
• TABLE 152 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Dystrophy, 2022-2032, USD (Million)

TABLE 153 Rest of Middle East and Africa Muscle Wasting Disorders Market By Muscular Atrophy, 2022-2032, USD (Million)

TABLE 154 Rest of Middle East and Africa Muscle Wasting Disorders Market By Treatment Type, 2022-2032, USD (Million)

• TABLE 155 Rest of Middle East and Africa Muscle Wasting Disorders Market By Physical Therapy, 2022-2032, USD (Million)

TABLE 156 Rest of Middle East and Africa Muscle Wasting Disorders Market By End-User, 2022-2032, USD (Million)

List of Figures

• FIG. 1 Global Muscle Wasting Disorders Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Muscle Wasting Disorders Market: Quality Assurance
• FIG. 5 Global Muscle Wasting Disorders Market, By Type, 2023
• FIG. 6 Global Muscle Wasting Disorders Market, By Treatment Type, 2023
• FIG. 7 Global Muscle Wasting Disorders Market, By End-User, 2023
• FIG. 8 Global Muscle Wasting Disorders Market, By Geography, 2023
• FIG. 9 Market Geographical Opportunity Matrix - Global Muscle Wasting Disorders Market, 2023

FIG. 10Market Positioning of Key Muscle Wasting Disorders Market Players, 2023

FIG. 11Global Muscle Wasting Disorders Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

• FIG. 12 Global Muscle Wasting Disorders Market, By Type, 2023 Vs 2032, %
• FIG. 13 Global Muscle Wasting Disorders Market, By Treatment Type, 2023 Vs 2032, %
• FIG. 14 Global Muscle Wasting Disorders Market, By End-User, 2023 Vs 2032, %
• FIG. 15 U.S. Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 16 Canada Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 17 Rest of North America Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 18 UK Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 19 Germany Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 20 Spain Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 21 Italy Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 22 France Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 23 Rest of Europe Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 24 China Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 25 Japan Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 26 India Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 27 Australia Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 28 South Korea Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 29 Rest of Asia Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 30 Brazil Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 31 Mexico Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 32 Rest of Latin America Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 33 GCC Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 34 Africa Muscle Wasting Disorders Market (US$ Million), 2022 - 2032
• FIG. 35 Rest of Middle East and Africa Muscle Wasting Disorders Market (US$ Million), 2022 - 2032

Muscle wasting disorders, characterized by the significant reduction of muscle mass and strength, have been the subject of increased medical attention over recent years. These conditions encompass a variety of diseases ranging from sarcopenia, typically related to aging, to neuromuscular disorders like muscular dystrophy. The muscle wasting disorders market is estimated to grow at a CAGR of 15.5% from 2024 to 2032.

Driver: Increasing Aging Population and Associated Sarcopenia

One of the primary drivers for the muscle wasting disorders market is the exponential rise in the global aging population. As the baby boomer generation enters the senior age bracket, the prevalence of sarcopenia - a muscle wasting condition closely associated with aging - has surged. According to the United Nations' report on World Population Aging, the number of individuals aged 60 years or older is expected to double by 2050. This demographic shift has led to an uptick in cases of sarcopenia. Compounded by the fact that muscle wasting exponentially increases the risk of physical disabilities, falls, fractures, and overall mortality, the healthcare industry's focus on combating this disorder has intensified. Treatment strategies ranging from hormone replacement therapies to strength training regimens have garnered attention, signifying the market's expansive potential.

Opportunity: Advancements in Genetic Therapies for Neuromuscular Disorders

The realm of genetic therapies has showcased promising results in addressing the root causes of certain muscle wasting disorders, especially those of a hereditary nature like muscular dystrophy. Recent case studies highlight instances where gene therapies have been successful in introducing or correcting specific genes, leading to improved muscle function and reduced disease progression. For instance, a publication in the New England Journal of Medicine detailed a gene therapy trial that demonstrated improved motor functions in children with a specific type of muscular dystrophy. As genetic research continues to unveil the underlying mutations causing these disorders, the opportunity to develop targeted therapies expands, potentially revolutionizing the treatment landscape.

Restraint: High Treatment Costs and Limited Accessibility

While advancements in treatment and management are promising, they come at a steep price. The costs associated with cutting-edge treatments, especially genetic therapies, are exorbitant. Many of these treatments are not universally covered by insurance, placing a significant financial burden on patients. Furthermore, the limited availability of specialized treatment centers, primarily in low-to-middle-income countries, restricts access to care. A study in the Journal of Clinical Medicine emphasized the significant disparities in the availability of neuromuscular disorder treatments across different regions, elucidating the market's challenges in achieving global reach.

Challenge: Variability in Clinical Presentation and Diagnostic Difficulties

Muscle wasting disorders present with a wide variability in clinical symptoms, often making early diagnosis challenging. Given that timely intervention is crucial to manage progression, this diagnostic delay can lead to compromised patient outcomes. Muscle biopsies, one of the gold standards in diagnosing certain muscle-wasting disorders, are invasive and might not always provide conclusive results. An article in the Muscle & Nerve journal highlighted instances where muscle biopsies yielded non-specific results, necessitating further diagnostic procedures. This variability not only prolongs the diagnostic journey but also amplifies the emotional and financial distress associated with these disorders.

Market Segmentation by Type

In terms of revenue generation, muscular dystrophy led the market segment in 2023. This can be attributed to its prevalence, especially in the pediatric population, and the high costs associated with its management, which include physiotherapy, surgical interventions, and medications. The research focus on dystrophic conditions, especially Duchenne Muscular Dystrophy (DMD), has paved the way for innovations in treatments like gene therapies and exon skipping drugs, further pushing the revenue envelope. In contrast, muscular atrophy, often a consequence of neuromuscular diseases or conditions like ALS, spinal muscular atrophy, or nerve injuries, demonstrated the highest Compound Annual Growth Rate (CAGR). The rising awareness, early diagnostic interventions, and burgeoning therapeutic pipelines for conditions like Spinal Muscular Atrophy (SMA) contribute to this growth trajectory, expected to continue from 2024 to 2032.

Market Segmentation by End-User

In 2023, hospitals emerged as the principal revenue contributor for the muscle wasting disorders market. This dominance was attributed to the comprehensive care offered, including diagnostics, therapeutics, surgeries, and rehabilitation, all under one roof. As multidisciplinary approaches became essential for managing these disorders, hospitals' holistic care model was preferred. However, from 2024 to 2032, it's expected that rehab centers will showcase the highest CAGR. As the emphasis shifts towards improving quality of life, maintaining mobility, and delaying disease progression, the role of rehabilitative therapies in muscle wasting disorders management becomes paramount. These centers, specializing in physiotherapy, occupational therapy, and speech therapy, among others, are becoming increasingly pivotal. Specialty clinics, focusing on niche therapeutic areas, and other segments like home care also play crucial roles, with patients seeking personalized, specialized care or preferring treatments within the comfort of their homes.

Market Segmentation by Region

North America, with its advanced healthcare infrastructure, research initiatives, and patient awareness, held the largest revenue share in 2023. The FDA's approval of drugs for conditions like DMD and SMA, coupled with the presence of major pharmaceutical players, propelled the region's dominance. However, the Asia-Pacific region is anticipated to exhibit the highest CAGR from 2024 to 2032. Factors like increasing healthcare expenditure, rising awareness of muscle wasting disorders, and improving diagnostic infrastructure contribute to this forecasted growth. Moreover, the burgeoning population and the presence of untapped markets present lucrative opportunities for market expansion in this region.

Competitive Trends

The muscle wasting disorders market is characterized by intense competition, with major players like Biogen, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.), PTC Therapeutics, Inc., and Teva Pharmaceutical Industries Ltd. leading the charge in 2023. These companies primarily focused on strategies like mergers, acquisitions, research collaborations, and aggressive R&D investments to maintain their market positions. For instance, Roche's acquisition of Spark Therapeutics accentuated its foothold in the gene therapy arena, especially concerning muscle wasting disorders. Additionally, the emphasis on patient assistance programs, ensuring drug accessibility even with high costs, became a notable strategy. Moving forward, from 2024 to 2032, it's expected that these players will continue their innovations, collaborations, and strategic alliances, driving the market forward.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Muscle Wasting Disorders market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Muscle Wasting Disorders market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Type

• Muscular Dystrophy
• Duchenne Muscular Dystrophy (DMD)
• Becker Muscular Dystrophy (BMD)
• Myotonic Muscular Dystrophy
• Congenital Muscular Dystrophy
• Limb-Girdle Muscular Dystrophy
• Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
  • Muscular Atrophy
• Physiologic Atrophy
• Pathologic Atrophy
• Neurogenic Atrophy

Treatment Type

• Medications
• Physical Therapy
• Ultrasound Therapy
• Electric Simulation
  • Nutritional Therapy
  • Surgery
  • Gene Therapy
  • Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

End-User

• Hospitals
• Rehab Centers
• Specialty Clinics
• Others (Homecare, etc.)

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Muscle Wasting Disorders market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Muscle Wasting Disorders market?

Which is the largest regional market for Muscle Wasting Disorders market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Muscle Wasting Disorders market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Muscle Wasting Disorders market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Muscle Wasting Disorders Market
• 2.2. Global Muscle Wasting Disorders Market, By Type, 2023 (US$ Million)
• 2.3. Global Muscle Wasting Disorders Market, By Treatment Type, 2023 (US$ Million)
• 2.4. Global Muscle Wasting Disorders Market, By End-User, 2023 (US$ Million)
• 2.5. Global Muscle Wasting Disorders Market, By Geography, 2023 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2023

3. Muscle Wasting Disorders Market: Competitive Analysis

• 3.1. Market Positioning of Key Muscle Wasting Disorders Market Vendors
• 3.2. Strategies Adopted by Muscle Wasting Disorders Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2023 Versus 2032

4. Muscle Wasting Disorders Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Muscle Wasting Disorders Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. Muscular Dystrophy
    • 5.3.1.1. Duchenne Muscular Dystrophy (DMD)
    • 5.3.1.2. Becker Muscular Dystrophy (BMD)
    • 5.3.1.3. Myotonic Muscular Dystrophy
    • 5.3.1.4. Congenital Muscular Dystrophy
    • 5.3.1.5. Limb-Girdle Muscular Dystrophy
    • 5.3.1.6. Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
  • 5.3.2. Muscular Atrophy
    • 5.3.2.1. Physiologic Atrophy
    • 5.3.2.2. Pathologic Atrophy
    • 5.3.2.3. Neurogenic Atrophy

6. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Medications
  • 6.3.2. Physical Therapy
    • 6.3.2.1. Ultrasound Therapy
    • 6.3.2.2. Electric Simulation
  • 6.3.3. Nutritional Therapy
  • 6.3.4. Surgery
  • 6.3.5. Gene Therapy
  • 6.3.6. Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)

7. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2023 Versus 2032
• 7.3. Market Segmentation
  • 7.3.1. Hospitals
  • 7.3.2. Rehab Centers
  • 7.3.3. Specialty Clinics
  • 7.3.4. Others (Homecare, etc.)

8. North America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 8.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 8.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 8.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 8.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 8.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 8.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 8.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

9. UK and European Union Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 9.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 9.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 9.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 9.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 9.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

10. Asia Pacific Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 10.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 10.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 10.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.4.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.4.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.5.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.5.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 10.5.1.6.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 10.5.1.6.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

11. Latin America Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 11.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 11.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 11.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 11.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 11.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 11.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 11.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

12. Middle East and Africa Muscle Wasting Disorders Market, 2022-2032, USD (Million)

• 12.1. Market Overview
• 12.2. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
• 12.3. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
• 12.4. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
• 12.5.Muscle Wasting Disorders Market: By Region, 2022-2032, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.1.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 12.5.1.1.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.2.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 12.5.1.2.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Muscle Wasting Disorders Market: By Type, 2022-2032, USD (Million)
      • 12.5.1.3.2. Muscle Wasting Disorders Market: By Treatment Type, 2022-2032, USD (Million)
      • 12.5.1.3.3. Muscle Wasting Disorders Market: By End-User, 2022-2032, USD (Million)

13. Company Profile

• 13.1. Biogen, Inc.
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. F. Hoffmann-La Roche Ltd
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. Novartis AG
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Ionis Pharmaceuticals, Inc.
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Sarepta Therapeutics, Inc.
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. PTC Therapeutics, Inc.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. Teva Pharmaceutical Industries Ltd.
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. Other Notable Players
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives